AU2019274815B2 - Prodrugs of fulvestrant - Google Patents

Prodrugs of fulvestrant Download PDF

Info

Publication number
AU2019274815B2
AU2019274815B2 AU2019274815A AU2019274815A AU2019274815B2 AU 2019274815 B2 AU2019274815 B2 AU 2019274815B2 AU 2019274815 A AU2019274815 A AU 2019274815A AU 2019274815 A AU2019274815 A AU 2019274815A AU 2019274815 B2 AU2019274815 B2 AU 2019274815B2
Authority
AU
Australia
Prior art keywords
hydroxy
methyl
compound
aryl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019274815A
Other languages
English (en)
Other versions
AU2019274815A1 (en
Inventor
Pathik Subhashchandra BRAHMKSHATRIYA
Vishalgiri Gunvantgiri GOSWAMI
Parva Yogeshchandra Purohit
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kashiv Biosciences LLC
Original Assignee
Kashiv Biosciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kashiv Biosciences LLC filed Critical Kashiv Biosciences LLC
Publication of AU2019274815A1 publication Critical patent/AU2019274815A1/en
Assigned to Shivanka Research LLC reassignment Shivanka Research LLC Request for Assignment Assignors: KASHIV BIOSCIENCES, LLC
Application granted granted Critical
Publication of AU2019274815B2 publication Critical patent/AU2019274815B2/en
Assigned to KASHIV BIOSCIENCES, LLC reassignment KASHIV BIOSCIENCES, LLC Request for Assignment Assignors: Shivanka Research LLC
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
AU2019274815A 2018-05-24 2019-05-24 Prodrugs of fulvestrant Active AU2019274815B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN201821019542 2018-05-24
IN201821019542 2018-05-24
IN201821047939 2018-12-18
IN201821047939 2018-12-18
PCT/IB2019/054315 WO2019224790A2 (en) 2018-05-24 2019-05-24 Prodrugs of fulvestrant

Publications (2)

Publication Number Publication Date
AU2019274815A1 AU2019274815A1 (en) 2021-01-21
AU2019274815B2 true AU2019274815B2 (en) 2024-11-07

Family

ID=68615936

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019274815A Active AU2019274815B2 (en) 2018-05-24 2019-05-24 Prodrugs of fulvestrant

Country Status (6)

Country Link
US (1) US20210253626A1 (enExample)
EP (1) EP3801553B1 (enExample)
JP (2) JP7384903B2 (enExample)
AU (1) AU2019274815B2 (enExample)
CA (1) CA3101421C (enExample)
WO (1) WO2019224790A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7384903B2 (ja) * 2018-05-24 2023-11-21 ケーアイ ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー フルベストラントのプロドラッグ
EP4061376A4 (en) * 2019-11-24 2024-03-13 Kashiv Biosciences, LLC Prodrugs of fulvestrant
WO2021172359A1 (ja) * 2020-02-25 2021-09-02 大日本住友製薬株式会社 Ｃｄｋ９阻害剤プロドラッグ及びそれを内封するリポソーム
WO2022034587A1 (en) * 2020-08-10 2022-02-17 Tnik Therapeutics Ltd Traf2- AND Nck-INTERACTING KINASE (TNIK) INHIBITORS AND USES THEREOF
CA3230353A1 (en) * 2021-08-23 2023-03-02 Sumitomo Pharma Co., Ltd. Self degradation-type cdk9 inhibitor prodrug and liposome encapsulating same
EP4422636A4 (en) * 2021-10-29 2025-09-03 Kashiv Biosciences Llc INECTABLE PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF BREAST CANCER
WO2023103929A1 (zh) * 2021-12-06 2023-06-15 江苏亚虹医药科技股份有限公司 氟维司群衍生物及其制备方法和医药用途
EP4444318A4 (en) * 2021-12-06 2026-01-28 Amneal Pharmaceuticals Llc COMPOUNDS FOR CANCER TREATMENT
CN119751533B (zh) * 2025-03-10 2026-01-13 山东大学 一种基于雌甾三烯结构的雌激素受体蛋白靶向降解嵌合体衍生物及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103421069A (zh) * 2013-05-23 2013-12-04 中国海洋大学 氟维司群磷酸酯衍生物及其制备方法和应用
US20160060288A1 (en) * 2013-04-18 2016-03-03 Xi'anlibang Pharmaceutical Technology Co., Ltd. Ester derivatives of 7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)-estra-1,3,5(10)-triene-3,17beta-diol having anticancer activity and preparation method thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
GB0008172D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Therapy
CN102600073B (zh) * 2012-03-31 2014-01-01 莱普德制药有限公司 以乳酸酯为基础的氟维司群或其衍生物油性制剂及其制备方法
US10112962B2 (en) 2014-07-02 2018-10-30 Xavier University Boron-based prodrug strategy for increased bioavailability and lower-dosage requirements for drug molecules containing at least one phenol (or aromatic hydroxyl) group
WO2019050850A1 (en) * 2017-09-05 2019-03-14 Primetime Life Sciences, Llc BIGUANIDINE DERIVATIVES OF THERAPEUTIC AGENTS, AND PREPARATION METHODS AND METHODS OF USING SAME
CN108159055A (zh) * 2018-01-04 2018-06-15 西安力邦医药科技有限责任公司 治疗乳腺癌的长效递药系统、其制备方法及应用
JP7384903B2 (ja) * 2018-05-24 2023-11-21 ケーアイ ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー フルベストラントのプロドラッグ

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160060288A1 (en) * 2013-04-18 2016-03-03 Xi'anlibang Pharmaceutical Technology Co., Ltd. Ester derivatives of 7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)-estra-1,3,5(10)-triene-3,17beta-diol having anticancer activity and preparation method thereof
CN103421069A (zh) * 2013-05-23 2013-12-04 中国海洋大学 氟维司群磷酸酯衍生物及其制备方法和应用

Also Published As

Publication number Publication date
JP7384903B2 (ja) 2023-11-21
JP2021525278A (ja) 2021-09-24
EP3801553A4 (en) 2022-04-27
EP3801553A2 (en) 2021-04-14
EP3801553B1 (en) 2026-03-25
CA3101421A1 (en) 2019-11-28
WO2019224790A2 (en) 2019-11-28
AU2019274815A1 (en) 2021-01-21
CA3101421C (en) 2024-06-18
WO2019224790A3 (en) 2020-01-16
JP2024016210A (ja) 2024-02-06
US20210253626A1 (en) 2021-08-19
JP7653092B2 (ja) 2025-03-28

Similar Documents

Publication Publication Date Title
AU2019274815B2 (en) Prodrugs of fulvestrant
US8916575B2 (en) Quinazoline derivatives for the treatment of viral infections and further diseases
ES2834065T3 (es) Inhibidores de arginasa y sus aplicaciones terapéuticas
AU2020290461B2 (en) Cot modulators and methods of use thereof
JP7688912B2 (ja) キノリンおよびキナゾリン化合物およびその使用方法
US8481724B2 (en) Synthesis of 2,4-pyrimidinediamines
EP3653628B1 (en) Methods of preparing cytotoxic benzodiazepine derivatives
CN111606861A (zh) 用于治疗病毒感染和另外的疾病的酰氨基嘧啶衍生物
US20230137764A1 (en) Prodrugs of fulvestrant
CA3179897A1 (en) Drug delivery system for locally delivering therapeutic agents and uses thereof
US20240398963A1 (en) Drug delivery system for locally delivering therapeutic agents and uses thereof
AU2024353116A1 (en) Halogen-substituted exatecan amide derivative, preparation method therefor, and use thereof
US20230391731A1 (en) Prodrugs for sustained releasing therapeutic agents and uses thereof
WO2023136589A1 (en) Fused heteroaryl hydroxamates as sting agonists
US10556887B2 (en) Processes for the preparation of Veliparib and intermediates thereof
JP7274415B2 (ja) ウイルス感染症および他の疾患を処置するためのピリミジンプロドラッグ
CN119431379B (zh) Wrn降解剂及其制备方法和应用
EP4099991A1 (en) Novel processes for preparation of tezacaftor
JPWO2008010571A1 (ja) ２’−シアノピリミジンヌクレオシド化合物
Hidayah et al. A Novel Synthesis Route of Phenyl Quinoline from Nitrochalcone with Hydrazine Hydrate in the Presence of Pd/C
HK40029973B (en) Methods of preparing cytotoxic benzodiazepine derivatives
BR122024023253A2 (pt) Compostos moduladores de cot, composições que os compreendem, usos dos mesmos, e kit
WO2019126842A1 (en) Therapeutic compounds and uses thereof
HK1252323B (en) Methods of preparing cytotoxic benzodiazepine derivatives
NZ625516B2 (en) Derivatives of betulin

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: SHIVANKA RESEARCH LLC

Free format text: FORMER APPLICANT(S): KASHIV BIOSCIENCES, LLC

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: KASHIV BIOSCIENCES, LLC

Free format text: FORMER OWNER(S): SHIVANKA RESEARCH LLC